What EU Governments Need To Do About Access To Affordable Medicines
In a wide-ranging discussion at the recent European Health Forum Gastein, policy makers explored big-picture challenges and ideas of what governments should do to ensure access to increasingly expensive medicines as pressures grow on national health care systems.
You may also be interested in...
A pricing simulation exercise at the recent EHFG conference gave delegates an idea of the multiple factors that have to be taken into account when setting the price of a new drug for a rare disease – and deciding which candidate molecules are worth investing in.
Speakers at the recent European Health Forum Gastein conference in Austria claimed that many new drugs don’t really bring a meaningful clinical benefit, and that new ways are needed to assess the value of innovation.
The BeNeLuxA initiative for improving access to medicines could soon include more countries, but much about the collaboration remains opaque for the pharmaceutical industry. Lawyer Koosje van Lessen Kloeke says constructive dialogue between the initiative and industry would benefit the collaboration.